Metabolic efficiency promotes protection from pressure overload in hearts expressing slow skeletal troponin I

Circulation: Heart Failure

Volumn 8, Issue 1, 2015, Pages 119-127

  Carley, Andrew N ^a   Taglieri, Domenico M ^a,b   Bi, Jian ^a   John Solaro, R ^a   Douglas Lewandowski, E ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b Department of Anesthesiology and Critical Care Medicine Maria Cecilia Hospital   (United States)

Author keywords

Contractile proteins; Energy metabolism; Enzymes; Hypertrophy

Indexed keywords

ADENOSINE TRIPHOSPHATE; CREATINE PHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MYOSIN HEAVY CHAIN BETA; PALMITIC ACID; PYRUVATE DEHYDROGENASE; PYRUVATE DEHYDROGENASE KINASE; PYRUVATE DEHYDROGENASE KINASE 4; SLOW SKELETAL TROPONIN I; TROPONIN I; UNCLASSIFIED DRUG; GLUCOSE;

ADULT; ANIMAL MODEL; AORTA CONSTRICTION; ARTICLE; CARBOXYLATION; DIASTOLIC DYSFUNCTION; DOWN REGULATION; ECHOCARDIOGRAPHY; FEMALE; GENE EXPRESSION; GLUCOSE OXIDATION; GLUCOSE UTILIZATION; HEART CONTRACTION; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE METABOLISM; HEART PERFUSION; HEART PROTECTION; HEART SIZE; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; ISOLATED HEART; LIPID OXIDATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; BIOSYNTHESIS; CARDIAC MUSCLE; DISEASE MODEL; ENERGY METABOLISM; METABOLISM; OXIDATION REDUCTION REACTION; SKELETAL MUSCLE; TRANSGENIC MOUSE;

ANIMALS; DISEASE MODELS, ANIMAL; ENERGY METABOLISM; GLUCOSE; HEART FAILURE; MICE; MICE, TRANSGENIC; MUSCLE, SKELETAL; MYOCARDIUM; OXIDATION-REDUCTION; TROPONIN I;

EID: 84927713453     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.114.001496     Document Type: Article

References (46)

1. Sorokina N, O'Donnell JM, McKinney RD, Pound KM, Woldegiorgis G, LaNoue KF, Ballal K, Taegtmeyer H, Buttrick PM, Lewandowski ED. Recruitment of compensatory pathways to sustain oxidative flux with reduced carnitine palmitoyltransferase I activity characterizes inefficiency in energy metabolism in hypertrophied hearts. Circulation. 2007;115:2033-2041. doi: 10.1161/CIRCULATIONAHA.106.668665.
2. O'Donnell JM, Fields AD, Sorokina N, Lewandowski ED. The absence of endogenous lipid oxidation in early stage heart failure exposes limits in lipid storage and turnover. J Mol Cell Cardiol. 2008;44:315-322. doi: 10.1016/j.yjmcc.2007.11.006.
3. Kolwicz SC Jr, Olson DP, Marney LC, Garcia-Menendez L, Synovec RE, Tian R. Cardiac-specific deletion of acetyl CoA carboxylase 2 prevents metabolic remodeling during pressure-overload hypertrophy. Circ Res. 2012;111:728-738. doi: 10.1161/CIRCRESAHA.112.268128.
4. Pound KM, Sorokina N, Ballal K, Berkich DA, Fasano M, Lanoue KF, Taegtmeyer H, O'Donnell JM, Lewandowski ED. Substrate-enzyme competition attenuates upregulated anaplerotic flux through malic enzyme in hypertrophied rat heart and restores triacylglyceride content: attenuating upregulated anaplerosis in hypertrophy. Circ Res. 2009;104:805-812. doi: 10.1161/CIRCRESAHA.108.189951.
5. Allard MF, Parsons HL, Saeedi R, Wambolt RB, Brownsey R. AMPK and metabolic adaptation by the heart to pressure overload. Am J Physiol Heart Circ Physiol. 2007;292:H140-H148. doi: 10.1152/ ajpheart.00424.2006.
6. Masoud WG, Ussher JR, Wang W, Jaswal JS, Wagg CS, Dyck JR, Lygate CA, Neubauer S, Clanachan AS, Lopaschuk GD. Failing mouse hearts utilize energy inefficiently and benefit from improved coupling of glycolysis and glucose oxidation. Cardiovasc Res. 2014;101:30-38. doi: 10.1093/cvr/cvt216.
7. Sack MN, Kelly DP. The energy substrate switch during development of heart failure: gene regulatory mechanisms (Review). Int J Mol Med. 1998;1:17-24.
8. Kolwicz SC Jr, Purohit S, Tian R. Cardiac metabolism and its interactions with contraction, growth, and survival of cardiomyocytes. Circ Res. 2013;113:603-616. doi: 10.1161/CIRCRESAHA.113.302095.
9. Ingwall JS. Energy metabolism in heart failure and remodelling. Cardiovasc Res. 2009;81:412-419. doi: 10.1093/cvr/cvn301.
10. Carley AN, Taegtmeyer H, Lewandowski ED. Matrix revisited: mechanisms linking energy substrate metabolism to the function of the heart. Circ Res. 2014;114:717-729. doi: 10.1161/CIRCRESAHA.114.301863.
11. Pereira RO, Wende AR, Crum A, Hunter D, Olsen CD, Rawlings T, Riehle C, Ward WF, Abel ED. Maintaining PGC-1 expression following pressure overload-induced cardiac hypertrophy preserves angiogenesis but not contractile or mitochondrial function. FASEB J. 2014;28:3691-3702. doi: 10.1096/fj.14-253823.
12. Young ME, Laws FA, Goodwin GW, Taegtmeyer H. Reactivation of peroxisome proliferator-activated receptor alpha is associated with contractile dysfunction in hypertrophied rat heart. J Biol Chem. 2001;276:44390-44395. doi: 10.1074/jbc.M103826200.
13. Pereira RO, Wende AR, Olsen C, Soto J, Rawlings T, Zhu Y, Anderson SM, Abel ED. Inducible overexpression of GLUT1 prevents mitochondrial dysfunction and attenuates structural remodeling in pressure overload but does not prevent left ventricular dysfunction. J Am Heart Assoc. 2013;2:e000301. doi: 10.1161/JAHA.113.000301.
14. Schwarzer M, Faerber G, Rueckauer T, Blum D, Pytel G, Mohr FW, Doenst T. The metabolic modulators, Etomoxir and NVP-LAB121, fail to reverse pressure overload induced heart failure in vivo. Basic Res Cardiol. 2009;104:547-557. doi: 10.1007/s00395-009-0015-5.
15. Pound KM, Arteaga GM, Fasano M, Wilder T, Fischer SK, Warren CM, Wende AR, Farjah M, Abel ED, Solaro RJ, Lewandowski ED. Expression of slow skeletal TnI in adult mouse hearts confers metabolic protection to ischemia. J Mol Cell Cardiol. 2011;51:236-243. doi: 10.1016/j.yjmcc.2011.05.014.
16. Arteaga GM, Palmiter KA, Leiden JM, Solaro RJ. Attenuation of length dependence of calcium activation in myofilaments of transgenic mouse hearts expressing slow skeletal troponin I. J Physiol. 2000;526 Pt 3:541-549.
17. Arteaga GM, Warren CM, Milutinovic S, Martin AF, Solaro RJ. Specific enhancement of sarcomeric response to Ca2+ protects murine myocardium against ischemia-reperfusion dysfunction. Am J Physiol Heart Circ Physiol. 2005;289:H2183-H2192. doi: 10.1152/ajpheart.00520.2005.
18. Taglieri DM, Monasky MM, Knezevic I, Sheehan KA, Lei M, Wang X, Chernoff J, Wolska BM, Ke Y, Solaro RJ. Ablation of p21-activated kinase-1 in mice promotes isoproterenol-induced cardiac hypertrophy in association with activation of Erk1/2 and inhibition of protein phosphatase 2A. J Mol Cell Cardiol. 2011;51:988-996. doi: 10.1016/j.yjmcc.2011.09.016.
19. Lewandowski ED, Doumen C, White LT, LaNoue KF, Damico LA, Yu X. Multiplet structure of 13C NMR signal from glutamate and direct detection of tricarboxylic acid (TCA) cycle intermediates. Magn Reson Med. 1996;35:149-154.
20. López JE, Myagmar BE, Swigart PM, Montgomery MD, Haynam S, Bigos M, Rodrigo MC, Simpson PC. myosin heavy chain is induced by pressure overload in a minor subpopulation of smaller mouse cardiac myocytes. Circ Res. 2011;109:629-638. doi: 10.1161/CIRCRESAHA.111.243410.
21. Fentzke RC, Buck SH, Patel JR, Lin H, Wolska BM, Stojanovic MO, Martin AF, Solaro RJ, Moss RL, Leiden JM. Impaired cardiomyocyte relaxation and diastolic function in transgenic mice expressing slow skeletal troponin I in the heart. J Physiol. 1999;517(pt 1):143-157.
22. Gibala MJ, Young ME, Taegtmeyer H. Anaplerosis of the citric acid cycle: role in energy metabolism of heart and skeletal muscle. Acta Physiol Scand. 2000;168:657-665. doi: 10.1046/j.1365-201x.2000.00717.x.
23. Smith CS, Bottomley PA, Schulman SP, Gerstenblith G, Weiss RG. Altered creatine kinase adenosine triphosphate kinetics in failing hypertrophied human myocardium. Circulation. 2006;114:1151-1158. doi: 10.1161/CIRCULATIONAHA.106.613646.
24. Xiong Q, Ye L, Zhang P, Lepley M, Tian J, Li J, Zhang L, Swingen C, Vaughan JT, Kaufman DS, Zhang J. Functional consequences of human induced pluripotent stem cell therapy: myocardial ATP turnover rate in the in vivo swine heart with postinfarction remodeling. Circulation. 2013;127:997-1008. doi: 10.1161/CIRCULATIONAHA.112.000641.
25. Peuhkurinen KJ. Regulation of the tricarboxylic acid cycle pool size in heart muscle. J Mol Cell Cardiol. 1984;16:487-495.
26. Wynn RM, Kato M, Chuang JL, Tso SC, Li J, Chuang DT. Pyruvate dehydrogenase kinase-4 structures reveal a metastable open conformation fostering robust core-free basal activity. J Biol Chem. 2008;283:25305-25315. doi: 10.1074/jbc.M802249200.
27. Lydell CP, Chan A, Wambolt RB, Sambandam N, Parsons H, Bondy GP, Rodrigues B, Popov KM, Harris RA, Brownsey RW, Allard MF. Pyruvate dehydrogenase and the regulation of glucose oxidation in hypertrophied rat hearts. Cardiovasc Res. 2002;53:841-851.
28. Razeghi P, Young ME, Alcorn JL, Moravec CS, Frazier OH, Taegtmeyer H. Metabolic gene expression in fetal and failing human heart. Circulation. 2001;104:2923-2931.
29. Mori J, Alrob OA, Wagg CS, Harris RA, Lopaschuk GD, Oudit GY. ANG II causes insulin resistance and induces cardiac metabolic switch and inefficiency: a critical role of PDK4. Am J Physiol Heart Circ Physiol. 2013;304:H1103-H1113. doi: 10.1152/ajpheart.00636.2012.
30. Houten SM, Chegary M, Te Brinke H, Wijnen WJ, Glatz JF, Luiken JJ, Wijburg FA, Wanders RJ. Pyruvate dehydrogenase kinase 4 expression is synergistically induced by AMP-activated protein kinase and fatty acids. Cell Mol Life Sci. 2009;66:1283-1294. doi: 10.1007/ s00018-009-9066-x.
31. Russell RR, Bergeron R, Shulman GI, Young LH. Translocation of myocardial glut-4 and increased glucose uptake through activation of AMPK by AICAR. Am J Physiol. 1999;277:H643-649.
32. Luiken JJ, Coort SL, Willems J, Coumans WA, Bonen A, van der Vusse GJ, Glatz JF. Contraction-induced fatty acid translocase/CD36 translocation in rat cardiac myocytes is mediated through AMP-activated protein kinase signaling. Diabetes. 2003;52:1627-1634.
33. Nagendran J, Waller TJ, Dyck JR. AMPK signalling and the control of substrate use in the heart. Mol Cell Endocrinol. 2013;366:180-193. doi: 10.1016/j.mce.2012.06.015.
34. Chatham JC, Young ME. Metabolic remodeling in the hypertrophic heart: fuel for thought. Circ Res. 2012;111:666-668. doi: 10.1161/ CIRCRESAHA.112.277392.
35. Lunde IG, Aronsen JM, Kvaløy H, Qvigstad E, Sjaastad I, Tønnessen T, Christensen G, Grønning-Wang LM, Carlson CR. Cardiac O-GlcNAc signaling is increased in hypertrophy and heart failure. Physiol Genomics. 2012;44:162-172. doi: 10.1152/physiolgenomics.00016.2011.
36. Facundo HT, Brainard RE, Watson LJ, Ngoh GA, Hamid T, Prabhu SD, Jones SP. O-GlcNAc signaling is essential for NFAT-mediated transcriptional reprogramming during cardiomyocyte hypertrophy. Am J Physiol Heart Circ Physiol. 2012;302:H2122-H2130. doi: 10.1152/ ajpheart.00775.2011.
37. Patterson AJ, Zhang L. Hypoxia and fetal heart development. Curr Mol Med. 2010;10:653-666.
38. Ascuitto RJ, Ross-Ascuitto NT. Substrate metabolism in the developing heart. Semin Perinatol. 1996;20:542-563.
39. Nickel A, Löffler J, Maack C. Myocardial energetics in heart failure. Basic Res Cardiol. 2013;108:358. doi: 10.1007/s00395-013-0358-9.
40. Lopaschuk GD, Collins-Nakai RL, Itoi T. Developmental changes in energy substrate use by the heart. Cardiovasc Res. 1992;26:1172-1180.
41. Wolska BM, Vijayan K, Arteaga GM, Konhilas JP, Phillips RM, Kim R, Naya T, Leiden JM, Martin AF, de Tombe PP, Solaro RJ. Expression of slow skeletal troponin I in adult transgenic mouse heart muscle reduces the force decline observed during acidic conditions. J Physiol. 2001;536(pt 3):863-870.
42. Urboniene D, Dias FA, Peña JR, Walker LA, Solaro RJ, Wolska BM. Expression of slow skeletal troponin I in adult mouse heart helps to maintain the left ventricular systolic function during respiratory hypercapnia. Circ Res. 2005;97:70-77. doi: 10.1161/01.RES.0000173849.68636.1e.
43. Kass DA, Solaro RJ. Mechanisms and use of calcium-sensitizing agents in the failing heart. Circulation. 2006;113:305-315. doi: 10.1161/ CIRCULATIONAHA.105.542407.
44. Westfall MV, Albayya FP, Turner II, Metzger JM. Chimera analysis of troponin I domains that influence Ca(2+)-activated myofilament tension in adult cardiac myocytes. Circ Res. 2000;86:470-477.
45. Westfall MV, Metzger JM. Single amino acid substitutions define isoformspecific effects of troponin I on myofilament Ca2+ and pH sensitivity. J Mol Cell Cardiol. 2007;43:107-118. doi: 10.1016/j.yjmcc.2007.05.017.
46. Day SM, Westfall MV, Fomicheva EV, Hoyer K, Yasuda S, La Cross NC, D'Alecy LG, Ingwall JS, Metzger JM. Histidine button engineered into cardiac troponin I protects the ischemic and failing heart. Nat Med. 2006;12:181-189. doi: 10.1038/nm1346.